Morpheus8 and EXION sit in the same rf microneedling category but take different approaches. Morpheus8 (InMode) uses Fractional RF Microneedling with bipolar RF and burst mode while EXION (BTL Industries) uses Fractional RF Microneedling + Targeted Ultrasound + AI-driven energy delivery. Both received FDA clearance (2020 and 2023 respectively) and both are actively sold in the US market. The decision between them is rarely about which is objectively better. It's about which fits your specific practice.
Physicians end up comparing these two devices when they're shopping in the $40,000-$60,000 to $30,000-$45,000 price range and want a category leader. Both devices are commonly recommended by sales reps from competing manufacturers, which means physicians often hear inflated claims about one and dismissive claims about the other. This comparison strips out the marketing and looks at pricing, mechanism, evidence, and practice fit side by side.
Side-by-Side Specifications
Morpheus8
EXION
Manufacturer
InMode
BTL Industries
Technology
Fractional RF Microneedling with bipolar RF and burst mode
Fractional RF Microneedling + Targeted Ultrasound + AI-driven energy delivery
Price (New)
$40,000-$60,000
$30,000-$45,000
Price (Used)
$25,000-$45,000
$14,000-$25,000
Treatment Time
15-60 minutes depending on area
20-30 minutes
Sessions
1-3 sessions
3-4 sessions
Per Session
$800-$2,500
$500-$1,500
Annual Consumables
$3,000-$8,000 (tips)
$2,000-$5,000
Annual Maintenance
$2,000-$5,000
$2,000-$4,000
FDA Cleared
Yes (2020)
Yes (2023)
Technology
Morpheus8
Technology: Fractional RF Microneedling with bipolar RF and burst mode. Deepest RF microneedling penetration (up to 8mm with body tip). Subdermal fat remodeling + collagen induction.
EXION
Technology: Fractional RF Microneedling + Targeted Ultrasound + AI-driven energy delivery. First RF microneedling platform with AI-driven energy optimization and integrated ultrasound. 4mm needle depth, 8mm RF thermal diffusion zone.
50+ published studies. Strong body of evidence for facial rejuvenation. Body application evidence is growing but thinner.
EXION
Emerging. Conference presentations and early peer-reviewed data. BTL investing heavily in clinical studies.
Treatment Experience
Morpheus8
15-60 minutes depending on area per session. Recommended protocol: 1-3 sessions. Treatment areas: Face, Neck, Body (abdomen, thighs, arms). Patients typically tolerate this platform well when operated by trained clinicians.
EXION
20-30 minutes per session. Recommended protocol: 3-4 sessions. Treatment areas: Face, Neck, Decolletage. Patient experience varies by operator training and settings.
Practice Fit
Morpheus8
Practices wanting the most recognized RF microneedling brand with body treatment capability. High-volume aesthetic practices where patient demand drives device selection.
EXION
BTL practices adding a skin platform to complement existing body devices. Practices wanting AI-driven energy optimization at a lower price than Morpheus8.
Pros and Cons
Morpheus8 Pros
Deepest penetration depth in the category (4mm face, 8mm body)
Strong brand recognition (highest consumer search volume in RF microneedling)
Body treatment capability (unique among RF microneedling platforms)
Can be combined with other InMode platforms (BodyTite, FaceTite)
Morpheus8 Cons
14 FDA adverse events in March 2026 alone (up from 3/mo baseline)
9 thermal injury reports, 3 scarring reports in recent MAUDE data
Consumable tip costs are significant
EXION Pros
AI-driven energy delivery (adjusts in real-time)
Combined RF microneedling + ultrasound in one platform
Lower price point than Morpheus8
BTL ecosystem integration (upsell path from Emsculpt/Emsella patients)
EXION Cons
Newer platform (2023), still building evidence base
No body treatment tip (face/neck only for now)
Lower brand recognition than Morpheus8
The Verdict
Choose Morpheus8 if your practice prioritizes InMode's ecosystem, brand recognition, or specific clinical advantages. Practices wanting the most recognized RF microneedling brand with body treatment capability. High-volume aesthetic practices where patient demand drives device selection. The pros that matter most: Deepest penetration depth in the category (4mm face, 8mm body); Strong brand recognition (highest consumer search volume in RF microneedling). The biggest tradeoff to accept: 14 FDA adverse events in March 2026 alone (up from 3/mo baseline).
Choose EXION if BTL Industries's positioning fits better. BTL practices adding a skin platform to complement existing body devices. Practices wanting AI-driven energy optimization at a lower price than Morpheus8. The pros that matter most: AI-driven energy delivery (adjusts in real-time); Combined RF microneedling + ultrasound in one platform. The biggest tradeoff to accept: Newer platform (2023), still building evidence base.
For a practice with limited capital that needs maximum flexibility, used pricing tilts the math. Morpheus8 used units run $25,000-$45,000; EXION used units run $14,000-$25,000. For practices with strong patient flow already, the device that integrates with your existing platforms is usually the right answer even if its standalone specs are slightly weaker. For practices building a category from scratch, brand recognition and patient demand matter more than raw clinical specs. Look at which device patients are already asking for in your market before signing a contract.
InMode vs BTL in RF Microneedling
This comparison represents InMode's flagship RF microneedling platform against BTL's entry into the category. EXION combines fractional RF microneedling with targeted ultrasound and AI-driven energy delivery. It is designed to slot into existing BTL practices that already run Emsculpt Neo, Emsella, or EXOMIND.
Morpheus8 has the deeper market penetration and stronger brand recognition. EXION has the lower price point ($30K-$45K vs $40K-$60K) and the BTL ecosystem advantage. For practices already in the BTL family, EXION's service, training, and bundling economics are compelling. For practices without existing BTL relationships, Morpheus8's proven track record and patient demand make it the safer bet.
AI Energy Delivery: Marketing or Meaningful?
EXION's AI-driven energy optimization adjusts parameters in real time based on tissue feedback. This is a genuine technical differentiator, not just marketing. It reduces operator dependency, which matters in practices where multiple clinicians perform treatments. Morpheus8 relies more on operator expertise to achieve consistent results.
However, AI-assisted doesn't mean AI-dependent. A skilled operator on Morpheus8 will outperform a less experienced operator on EXION despite the AI assistance. The technology narrows the skill gap but doesn't eliminate it.
Frequently Asked Questions
Which is more expensive, Morpheus8 or EXION?
Morpheus8 runs $40,000-$60,000 new and $25,000-$45,000 used. EXION runs $30,000-$45,000 new and $14,000-$25,000 used. Per-session pricing is $800-$2,500 for Morpheus8 and $500-$1,500 for EXION. Annual operating costs (consumables plus maintenance) typically run 5-15% of purchase price for both devices. The right financial comparison includes total cost of ownership over 5 years, not just sticker price.
Which has better clinical evidence, Morpheus8 or EXION?
Morpheus8 clinical evidence: 50+ published studies. Strong body of evidence for facial rejuvenation. Body application evidence is growing but thinner. EXION clinical evidence: Emerging. Conference presentations and early peer-reviewed data. BTL investing heavily in clinical studies. Evidence quality is not about study count alone. Look at sample sizes, blinded evaluators, independence from manufacturer funding, and outcome durability. Older devices in the same category usually have stronger evidence because they've been studied longer.
Is Morpheus8 or EXION more popular in dermatology practices?
Both Morpheus8 and EXION are commonly used in dermatology, plastic surgery, med spa practices. Market share in any given category shifts year to year. InMode and BTL Industries both maintain active sales forces in the US. Ask other physicians in your specialty which platform they're using and why. Peer references in your local market matter more than national market share data.
Are there safety concerns with Morpheus8 or EXION?
Both devices are FDA cleared and have established safety profiles. Morpheus8 has these documented concerns: 14 FDA adverse events in March 2026 alone (up from 3/mo baseline). EXION has: Newer platform (2023), still building evidence base. Physicians should monitor FDA MAUDE reports for both devices before purchase. Adverse event trends matter because they signal problems that may not appear in marketing materials. Any device with a sudden spike in MAUDE filings deserves closer scrutiny.
Can I use Morpheus8 and EXION in the same practice?
Some practices run both devices, especially when they target different patient segments or treatment areas. The downside is duplicated training, parallel consumable inventories, and potential cannibalization between platforms. The upside is broader marketing claims and the ability to switch patients between platforms if one doesn't deliver expected results. Most practices choose one and commit to mastering it rather than splitting volume.
What's the resale value comparison between Morpheus8 and EXION?
Used Morpheus8 sells for $25,000-$45,000 on the secondary market. Used EXION sells for $14,000-$25,000. Resale values depend on age, software version, applicator condition, and remaining warranty. Devices with strong installed bases hold value better. Devices with active safety signals or declining manufacturer financial health depreciate faster. Resale value should be a factor in any device purchase, especially if practice plans might change in 3-5 years.
Morpheus8 vs EXION: which is better for dermatology practices in 2026?
For dermatology practices specifically in 2026, the choice between Morpheus8 and EXION depends on three factors: existing equipment compatibility (does the new device integrate with what you already run), patient mix and treatment volume (high-volume practices typically benefit from Morpheus8's deepest penetration depth in the category (4mm face, 8mm body) while lower-volume practices often prefer EXION's ai-driven energy delivery (adjusts in real-time)), and total cost of ownership over 5 years including consumables and maintenance. Run the side-by-side TCO analysis with realistic patient volume projections before committing to either platform.
Morpheus8 vs EXION: 2026 update on features and clinical evidence?
As of April 2026, both Morpheus8 and EXION continue commercial availability from InMode and BTL Industries respectively. Recent updates worth tracking: software releases, new applicator launches, expanded FDA labeling indications, and new peer-reviewed clinical evidence publications. Manufacturer financial stability also matters for long-term support and parts availability. Both manufacturers share business updates periodically that inform the long-term outlook for each device.
How do I choose between Morpheus8 and EXION for my practice?
Use a structured decision framework: list 5-7 must-have requirements specific to your patient mix and practice economics, score Morpheus8 and EXION against each requirement on a 1-5 scale, weight the requirements by importance, then sum the weighted scores. The platform that scores meaningfully higher (10%+ gap) is the right choice. If the scores are within 10%, secondary factors decide: manufacturer relationship, financing terms, training availability, and resale value. Avoid choosing based on feature breadth alone because most devices in this category have similar feature checkboxes. The differentiation is in workflow fit, treatment results, and total cost over 5 years.
Are there better alternatives to Morpheus8 or EXION in the rf microneedling category?
In the rf microneedling category, Morpheus8 and EXION are often the leading platforms but other alternatives may fit specific practice profiles better. Other category options include genius, vivace, potenza. Run a 4-platform shortlist evaluation rather than a 2-platform binary because hidden alternatives sometimes outperform on the metrics that matter most to your specific practice.